Robotic colorectal cancer surgery offers improved early post-operative clinical and oncological outcomes
EAES Academy. Karategos A. 07/05/22; 363116; P161
Athanasios Karategos
Contributions
Contributions
Abstract
Background:
Robotic surgery represents the newest minimally invasive technology available to reduce the impact of surgery and provides unique benefits in pelvic access of the technically challenging colorectal resections. The purpose of this study was to assess the feasibility, clinical and oncological outcomes of robotic surgery for patients with colorectal cancer.
Methods:
This is a single-institution prospective study evaluating all patients with colorectal cancer undergoing robotic resection between October 2020 to December 2021 at our trust. Demographic data, perioperative and 30-day postoperative outcomes were assessed. The feasibility techniques and clinical outcomes were documented and data were analysed.
Results:
A total of 100 robotic cases were performed of which 68 are due to colorectal cancer. Fifty-seven per cent (n=39/68) had sigmoid cancer followed by right sided colon cancer in 27%(n=18/68) and rectal cancer in 20%(n=14/68). The M:F ratio was 2:1, median age of diagnosis was 68 (36-88) years and BMI of 29 (18-41) kg/m2. Forty-two patients underwent Anterior Resection (34% High ,28% Low), 17 (25%) Right Hemicolectomy, 3 (5%) patients underwent panproctocolectomy and 2 (3%) abdominoperineal excision. A covering loop ileostomy was formed in patients with low rectal cancer. There were no conversions to open surgery. Anastomotic leak (Clavien-Dindo grade IV) was noted in 1.4%(n=1/68) of patients. Return of gut function, as defined by tolerating oral diet and passing flatus, was noted within 48 hours in 91% of the patients (n=62). All patients were discharged on their baseline Hb with no need for iron replacement therapy or blood transfusion. The median length of hospital stay was 5 days. Forty-four per cent of patients underwent adjuvant chemotherapy. Pathologically complete resection (R0) was achieved in all patients with a median lymph node ratio of 0.14. There was no reported 30-day mortality.
Conclusion:
Robotic surgery for colorectal cancer is a feasible and safe approach ensuring that surgery remains minimally invasive, leading to a significant reduction in length of hospital stay, a rapid postoperative recovery and an earlier return of gut function.
Robotic surgery represents the newest minimally invasive technology available to reduce the impact of surgery and provides unique benefits in pelvic access of the technically challenging colorectal resections. The purpose of this study was to assess the feasibility, clinical and oncological outcomes of robotic surgery for patients with colorectal cancer.
Methods:
This is a single-institution prospective study evaluating all patients with colorectal cancer undergoing robotic resection between October 2020 to December 2021 at our trust. Demographic data, perioperative and 30-day postoperative outcomes were assessed. The feasibility techniques and clinical outcomes were documented and data were analysed.
Results:
A total of 100 robotic cases were performed of which 68 are due to colorectal cancer. Fifty-seven per cent (n=39/68) had sigmoid cancer followed by right sided colon cancer in 27%(n=18/68) and rectal cancer in 20%(n=14/68). The M:F ratio was 2:1, median age of diagnosis was 68 (36-88) years and BMI of 29 (18-41) kg/m2. Forty-two patients underwent Anterior Resection (34% High ,28% Low), 17 (25%) Right Hemicolectomy, 3 (5%) patients underwent panproctocolectomy and 2 (3%) abdominoperineal excision. A covering loop ileostomy was formed in patients with low rectal cancer. There were no conversions to open surgery. Anastomotic leak (Clavien-Dindo grade IV) was noted in 1.4%(n=1/68) of patients. Return of gut function, as defined by tolerating oral diet and passing flatus, was noted within 48 hours in 91% of the patients (n=62). All patients were discharged on their baseline Hb with no need for iron replacement therapy or blood transfusion. The median length of hospital stay was 5 days. Forty-four per cent of patients underwent adjuvant chemotherapy. Pathologically complete resection (R0) was achieved in all patients with a median lymph node ratio of 0.14. There was no reported 30-day mortality.
Conclusion:
Robotic surgery for colorectal cancer is a feasible and safe approach ensuring that surgery remains minimally invasive, leading to a significant reduction in length of hospital stay, a rapid postoperative recovery and an earlier return of gut function.
Background:
Robotic surgery represents the newest minimally invasive technology available to reduce the impact of surgery and provides unique benefits in pelvic access of the technically challenging colorectal resections. The purpose of this study was to assess the feasibility, clinical and oncological outcomes of robotic surgery for patients with colorectal cancer.
Methods:
This is a single-institution prospective study evaluating all patients with colorectal cancer undergoing robotic resection between October 2020 to December 2021 at our trust. Demographic data, perioperative and 30-day postoperative outcomes were assessed. The feasibility techniques and clinical outcomes were documented and data were analysed.
Results:
A total of 100 robotic cases were performed of which 68 are due to colorectal cancer. Fifty-seven per cent (n=39/68) had sigmoid cancer followed by right sided colon cancer in 27%(n=18/68) and rectal cancer in 20%(n=14/68). The M:F ratio was 2:1, median age of diagnosis was 68 (36-88) years and BMI of 29 (18-41) kg/m2. Forty-two patients underwent Anterior Resection (34% High ,28% Low), 17 (25%) Right Hemicolectomy, 3 (5%) patients underwent panproctocolectomy and 2 (3%) abdominoperineal excision. A covering loop ileostomy was formed in patients with low rectal cancer. There were no conversions to open surgery. Anastomotic leak (Clavien-Dindo grade IV) was noted in 1.4%(n=1/68) of patients. Return of gut function, as defined by tolerating oral diet and passing flatus, was noted within 48 hours in 91% of the patients (n=62). All patients were discharged on their baseline Hb with no need for iron replacement therapy or blood transfusion. The median length of hospital stay was 5 days. Forty-four per cent of patients underwent adjuvant chemotherapy. Pathologically complete resection (R0) was achieved in all patients with a median lymph node ratio of 0.14. There was no reported 30-day mortality.
Conclusion:
Robotic surgery for colorectal cancer is a feasible and safe approach ensuring that surgery remains minimally invasive, leading to a significant reduction in length of hospital stay, a rapid postoperative recovery and an earlier return of gut function.
Robotic surgery represents the newest minimally invasive technology available to reduce the impact of surgery and provides unique benefits in pelvic access of the technically challenging colorectal resections. The purpose of this study was to assess the feasibility, clinical and oncological outcomes of robotic surgery for patients with colorectal cancer.
Methods:
This is a single-institution prospective study evaluating all patients with colorectal cancer undergoing robotic resection between October 2020 to December 2021 at our trust. Demographic data, perioperative and 30-day postoperative outcomes were assessed. The feasibility techniques and clinical outcomes were documented and data were analysed.
Results:
A total of 100 robotic cases were performed of which 68 are due to colorectal cancer. Fifty-seven per cent (n=39/68) had sigmoid cancer followed by right sided colon cancer in 27%(n=18/68) and rectal cancer in 20%(n=14/68). The M:F ratio was 2:1, median age of diagnosis was 68 (36-88) years and BMI of 29 (18-41) kg/m2. Forty-two patients underwent Anterior Resection (34% High ,28% Low), 17 (25%) Right Hemicolectomy, 3 (5%) patients underwent panproctocolectomy and 2 (3%) abdominoperineal excision. A covering loop ileostomy was formed in patients with low rectal cancer. There were no conversions to open surgery. Anastomotic leak (Clavien-Dindo grade IV) was noted in 1.4%(n=1/68) of patients. Return of gut function, as defined by tolerating oral diet and passing flatus, was noted within 48 hours in 91% of the patients (n=62). All patients were discharged on their baseline Hb with no need for iron replacement therapy or blood transfusion. The median length of hospital stay was 5 days. Forty-four per cent of patients underwent adjuvant chemotherapy. Pathologically complete resection (R0) was achieved in all patients with a median lymph node ratio of 0.14. There was no reported 30-day mortality.
Conclusion:
Robotic surgery for colorectal cancer is a feasible and safe approach ensuring that surgery remains minimally invasive, leading to a significant reduction in length of hospital stay, a rapid postoperative recovery and an earlier return of gut function.
{{ help_message }}
{{filter}}